cd47 - Robuta Search

https://pmc.ncbi.nlm.nih.gov/articles/PMC9746883/ Elevated CD47 is a hallmark of dysfunctional, aged muscle stem cells that can be targeted to... In aging, skeletal muscle strength and regenerative capacity declines due, in part, to functional impairment of muscle stem cells (MuSCs), yet the underlying... https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd47-monoclonal-antibody-zl-1201 Definition of anti-CD47 monoclonal antibody ZL-1201 - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of anti cd47 monoclonal antibody https://www.fiercebiotech.com/biotech/synthon-taps-dutch-blood-donor-group-for-cd47-program Synthon taps Dutch blood donor group for CD47 program | Fierce Biotech Mar 2, 2017 - The organization that runs the Netherlands' network of blood donors, Sanquin, knows a thing or two about hematology, and it turns out also cancer. blood donor synthon taps dutch https://elifesciences.org/articles/04586 Registered report: The CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic... https://en.wikipedia.org/wiki/CD47 CD47 - Wikipedia cd47 wikipedia https://drive.google.com/file/d/1mzDZqm8CNsojj9W9tIq5fbTTGx8ROdQj/view Prediction of target receptor occupancy for ALX148, a CD47 blocker, using mechanistic PK/RO... https://www.biospace.com/fapon-biopharma-s-anti-cd47-antibody-fp002-earns-ind-approval-from-fda Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA - BioSpace Feb 22, 2023 - Fapon Biopharma has been approved by FDA for clinical trials. https://www.biospace.com/akeso-published-results-from-cd47-antibody-ligufalimab-in-combination-with-azacitidine-for-newly-diagnosed-higher-risk-myelodysplastic-syndrome-and-treatment-naive-acute-myeloid-leukemia-at-ash-2023 Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly... Dec 15, 2023 - Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with... https://www.fiercebiotech.com/biotech/abbvie-stops-second-cd47-study-early-dropping-out-aml-race-it-joined-2b-biobuck-deal AbbVie stops 2nd CD47 study early, dropping out of AML race Aug 17, 2022 - Weeks after pulling the plug on a multiple myeloma trial, AbbVie is halting a phase 1b trial that is testing the anti-CD47 antibody in AML and MDS. dropping out of abbvie stops 2nd cd47 https://elifesciences.org/articles/18173/figures Figures and data in Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction... Editors' Summary: The results in this Replication Study could not be interpreted. figures and data